Onkológia 1/2012
Crizotinib – a new molecule in the treatment of lung cancer?
Crizotinib is a new molecule that attracted great attention in the treatment of lung cancer in 2010. Crizotinib (PF-02341066) is a selective ATP-competitive inhibitor of anaplastic lymphoma tyrosine kinase (ALK). The treatment with crizotinib has brought remarkable results in phases 1/2 study in case of patients with non-small cell lung cancer with activated ALK. This article is a brief review of current knowledge about this new drug.
Keywords: crizotinib, EML4-ALK rearrangement, study A8081001.
